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Cells of the mononuclear phagocyte system are part of
the innate immune system and function as a first line
of defense, sensing, ingesting, and destroying foreign
antigens and pathogens and directing subsequent
inflammatory responses. Two of the main components
of the mononuclear phagocyte system are monocytes
(Mo) and macrophages (Mφ). Mo are derived from
bone marrow precursors and provide immune surveil-
lance in the bloodstream. Mφ primarily reside in the
tissues, and are the main regulators of tissue home-
ostasis and repair. Tissue-resident Mφ have two dis-
tinct origins. Most tissue-resident Mφ are established
prenatally and are maintained by self-renewal [1]. A
smaller subset of tissue-resident Mφ develops from
recruited Mo that differentiate into Mφ under the
guidance of growth factors and other inflammatory
stimuli [1]. Mo-derived Mφ play a prominent role in
tissue inflammation and pathology, including infection
control and cancer development. It is therefore critical
to better understand the pathways involved in the dif-
ferentiation of Mo into Mφ, so targeted therapies can
be developed to improve outcomes in diseases medi-
ated by these cells. Mo-derived Mφ subset heterogene-
ity is tightly controlled by defined transcriptional
networks [2]. Although these networks have been rela-
tively well mapped out, the regulation of specific tran-
scription factors in stage- and lineage-specific Mo to
Mφ differentiation is not well understood.
In this issue of The FEBS Journal, Jin et al. assessed
how changes in histone modifications impacted the
transcriptional regulation of Mo to Mφ differentiation
[3]. Histone modifications stimulate or repress gene
transcription by altering chromatin structure, and have
been shown to regulate normal developmental changes
in the immune system and contribute to cell lineage
decisions and differentiation [4,5]. This makes them an
attractive area to explore in the regulation of Mo to
Mφ differentiation. The present report provides impor-
tant evidence that alterations in the Mo histone
modification landscape underlie broad changes in tran-
scription factor expression critical in the process of
Mo to Mφ differentiation.
There are numerous transcription factors involved in
the differentiation of Mo to Mφ, and these differ
based on the specific Mφ subset. Regardless of the ter-
minal Mφ differentiation state, the transcription fac-
tors involved need to be precisely regulated in order
for appropriately functional Mφ to develop. Key tran-
scription factors involved in general Mo to Mφ differ-
entiation that were evaluated in the present study
include the positive regulators Kr€uppel-like factor 4
(KLF4) and the forkhead box O family (FOXO), as
well as the homeobox A gene cluster (HOXA) which
acts to block this differentiation [6–8]. Aberrant
expression or function of any of these or other tran-
scription factors can lead to the development of acute
myelogenous leukemia, highlighting the importance of
transcriptional regulation in maintaining tissue home-
ostasis and appropriate Mφ differentiation and func-
tion [8].
Epigenetic modifications alter chromatin structure
and change the ability of transcription factors to inter-
act with the DNA, thus allowing for precise gene expres-
sion regulation without altering the underlying genetic
code. The chemical modification of lysine residues in
histone tails is one type of epigenetic modification, and
the position of the modified lysine within the histone
sequence determines whether the added modification
results in an active (open) or silenced (closed) gene con-
figuration. Activation of gene transcription occurs when
three methyl groups are added to lysine (K) 4 of histone
(H) 3 (i.e., H3K4me3). Conversely, H3K27me3 results
in chromatin compaction and gene repression [9]. There
are numerous enzymes that add modifications to histone
proteins, called histone methyltransferases (HMTs),
controlling the gene expression profile of a cell and
allowing for plasticity during cell activation and differ-
entiation. The mixed lineage leukemia (MLL) protein
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family and the enhancer of zeste homolog 2 (EZH2) are
HMTs that trimethylate histone 3 lysine 4 and histone 3
lysine 27, resulting in H3K4me3 and H3K27me3,
respectively [10].
The roles of MLL and EZH2 have been most exten-
sively studied in cancer states, but there has recently
been increased interest in the contribution of these
HMTs to immune cell activation and differentiation. In
recent years, both MLL and EZH2 have been found to
have crucial roles in T-cell proliferation, differentiation,
and maintenance of lineage phenotypes [11,12]. Simi-
larly, these HMTs have been shown to contribute to
Mo to Mφ differentiation and the maintenance of speci-
fic Mφ phenotypes [8,13]. The present study adds to this
body of literature by demonstrating that both MLL
and EZH2 cause site-specific changes in H3K4me3 and
H3K27me3 at the promoters of the transcription fac-
tors KLF4, FOXO, and HOXA, which are important
in the regulation of Mo to Mφ differentiation (Fig. 1).
A strength of this study is the use of pharmacologic
inhibition of these HMTs, which promotes Mo to Mφ
differentiation and opens up the possibility of using an
HMT inhibitor in disease states in which aberrant Mo
to Mφ differentiation is involved. While further work is
needed to dissect the exact upstream mechanisms
underlying these results, this study supports the notion
that site-specific histone methylation and subsequent
chromatin remodeling at known immunologically
important transcription factor promoters is a critical
step in Mo to Mφ differentiation.
These findings set the stage for potential therapeutic
targets to alter the process of Mo to Mφ differentia-
tion, which is crucial to the development of many seri-
ous disease states, including leukemia, obesity, and
atherosclerosis [14]. HMT inhibitors are attractive
treatment options for these diseases; some inhibitors
have reached the early stages of clinical trials in can-
cer, including an EZH2 inhibitor used to treat B-cell
lymphoma [15]. However, challenges remain when con-
sidering using HMT inhibitors to treat human disease
states. One such challenge includes off-target effects
and toxicities of HMT inhibitors due to the compli-
cated biology of HMTs, which have numerous and
diverse targets that differ between cell types. This
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Fig. 1. Schematic overview of histone methylation changes impacting transcription factor expression in monocyte to macrophage
differentiation. The upper portion of the figure demonstrates that macrophage differentiation factors stimulate decreased monocyte
H3K27me3 at the promoter sites of KLF4, FOXO1, and FOXO3, causing the chromatin to open, allowing transcription factors to access the
promoter sites, and resulting in increased gene transcription. The lower portion of the figure demonstrates that macrophage differentiation
factors stimulate decreased monocyte H3K4me3 and increased H3K27me3 at the promoter sites of HOXA6, HOXA7, and HOXA13, causing
the chromatin to close, denying transcription factors access to the promoter sites, and resulting in decreased gene transcription.
1307The FEBS Journal 284 (2017) 1306–1308 ª 2017 Federation of European Biochemical Societies
Commentary
makes systemic administration of an HMT inhibitor
complicated and risky, highlighting the importance of
studies that further detail the intricacies of HMT tar-
gets in varied cell types under different conditions.
Only in further understanding how and why HMTs
select their targets and why this differs between cell
types and upon different stimulating conditions can we
move forward in developing safe and effective thera-
pies to treat these diseases while minimizing off-target
effects.
Mo-derived Mφ play an important role in many dis-
ease states, and defined transcriptional networks
tightly regulate the process of Mo to Mφ differentia-
tion. Some of these networks are under the direct con-
trol of the HMTs MLL and EZH2, resulting in
increased H3K4me3 and H3K27me3 and subsequent
chromatin remodeling at the promoter sites of tran-
scription factors crucial in Mo to Mφ differentiation.
These findings identify potential therapeutic targets for
diseases in which Mφ play a prominent role, although
better understanding of the nuanced regulation of
these HMTs and their specific targets is necessary
before directed epigenetic treatments can be widely
implemented.
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